Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals

Journal of Neural Transmission

Volumn 120, Issue 10, 2013, Pages 1411-1419

  Horn, Anne ^a   Scheller, Carsten ^a   Du Plessis, Stefan ^b   Arendt, Gabriele ^c   Nolting, Thorsten ^c   Joska, John ^d   Sopper, Sieghart ^e   Maschke, Matthias ^f   Obermann, Mark ^f   Husstedt, Ingo W ^g   Hain, Johannes ^a   Maponga, Tongai ^b   Riederer, Peter ^a   Koutsilieri, Eleni ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

CSF; DAT; Dopamine; HAND; HIV; Polymorphism

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER;

ADULT; ALLELE; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE SEVERITY; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AFRICA;

ADULT; AGED; AIDS DEMENTIA COMPLEX; ALLELES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84885428546     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1086-x     Document Type: Article

References (41)

1. Buttarelli FR, Fanciulli A, Pellicano C, Pontieri FE (2011) The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders. Curr Neuropharmacol 9:278-288
2. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26:307-319
3. Congdon E, Lesch KP, Canli T (2008) Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. Am J Med Genet B Neuropsychiatr Genet 147B:27-32
4. Cornish KM, Manly T, Savage R, Swanson J, Morisano D, Butler N, Grant C, Cross G, Bentley L, Hollis CP (2005) Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample. Mol Psychiatry 10:686-698
5. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Muller JG, Pedersen V, Gsell W, Heeney JL, Gerlach M, Gosztonyi G, Riederer P, ter Meulen V (2001) Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 101:85-91
6. Evans SR, Yeh TM, Sacktor N, Clifford DB, Simpson D, Miller EN, Ellis RJ, Valcour V, Marra CM, Millar L, Schifitto G (2007) Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 8:437-446
7. Gelman BB, Spencer JA, Holzer CE 3rd, Soukup VM (2006) Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 1:410-420
8. Giros B, Caron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14:43-49
9. Gupta S, Bousman CA, Chana G, Cherner M, Heaton RK, Deutsch R, Ellis RJ, Grant I, Everall IP (2011) Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. J Neurovirol 17:239-247
10. Hawi Z, Segurado R, Conroy J, Sheehan K, Lowe N, Kirley A, Shields D, Fitzgerald M, Gallagher L, Gill M (2005) Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. Am J Hum Genet 77:958-965
11. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR (2000) Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:133-139
12. Jacobs GB, Loxton AG, Laten A, Robson B, van Rensburg EJ, Engelbrecht S (2009) Emergence and diversity of different HIV-1 subtypes in South Africa, 2000-2001. J Med Virol 81:1852-1859
13. Kang AM, Palmatier MA, Kidd KK (1999) Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 46:151-160
14. Koutsilieri E, Gotz ME, Sopper S, Stahl-Hennig C, Czub M, ter Meulen V, Riederer P (1997) Monoamine metabolite levels in CSF of SIV-infected rhesus monkeys (Macaca mulatta). NeuroReport 8:3833-3836
15. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P (2002) Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm 109:399-410
16. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, Kumar M (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15:257-274
17. Lamensdorf I, Porat S, Simantov R, Finberg JP (1999) Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol 126:997-1002
18. Levine AJ, Sinsheimer JS, Bilder R, Shapshak P, Singer EJ (2012) Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV + adults. J Clin Exp Neuropsychol 34:78-91
19. Maragos WF, Young KL, Turchan JT, Guseva M, Pauly JR, Nath A, Cass WA (2002) Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 83:955-963
20. Mata R, Hau R, Papassotiropoulos A, Hertwig R (2012) DAT1 polymorphism is associated with risk taking in the Balloon Analogue Risk Task (BART). PLoS One 7:e39135
21. Mill J, Asherson P, Browes C, D'Souza U, Craig I (2002) Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114:975-979
22. Mothobi NZ, Brew BJ (2012) Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 25:4-9
23. Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, Albert J, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Coughlan S, Costagliola D, De Luca A, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hoepelman I, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, Macrae E, Maljkovic-Berry I, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen MO, Schmit JC, Schuurman R, Soriano V, Stanczak J, Stanojevic M, Struck D, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CA, Vandamme AM (2009) Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology 6:49
24. Pontieri FE, Colosimo C (2010) Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease. Mov Disord 25:125-126
25. Power C, Selnes OA, Grim JA, McArthur JC (1995) HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 8:273-278
26. Purohit V, Rapaka R, Shurtleff D (2011) Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44:102-110
27. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz MH (2001) Attention-deficit hyperactivity disorder: a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet 105:471-478
28. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E (2005) The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 19:1367-1374
29. Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS (2001) Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4 + and CD8 + T cells in vitro: a receptor-mediated mechanism. NeuroImmunoModulation 9:23-33
30. Sakamoto M, Marcotte TD, Umlauf A, Franklin D Jr, Heaton RK, Ellis RJ, Letendre S, Alexander T, McCutchan JA, Morgan EE, Woods SP, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson D, Grant I (2013) Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr 62:36-42
31. Sardar AM, Czudek C, Reynolds GP (1996) Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. NeuroReport 7:910-912
32. Scheller C, Sopper S, Jassoy C, ter Meulen V, Riederer P, Koutsilieri E (2000) Dopamine activates HIV in chronically infected T lymphoblasts. J Neural Transm 107:1483-1489
33. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Grunblatt E, ter Meulen V, Riederer P, Koutsilieri E (2005) Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem 95:377-387
34. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, Obermann M, Angerer A, Husstedt IW, Meisner F, Neuen-Jacob E, Muller HW, Carey P, Ter Meulen V, Riederer P, Koutsilieri E (2010) Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm 117:699-705
35. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, Hung VL, Miller EN, Smith E, Ellis RJ, Valcour V, Singer E, Marra CM, Kolson D, Weihe J, Remmel R, Katzenstein D, Clifford DB (2007) A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 69:1314-1321
36. Uhl GR (2003) Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 18(Suppl 7):S71-S80
37. van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J (2009) Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med 50:45-52
38. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-1106
39. Wagner AK, Ren D, Conley YP, Ma X, Kerr ME, Zafonte RD, Puccio AM, Marion DW, Dixon CE (2007) Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury. J Neurosurg 106:538-547
40. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS (2004) Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127:2452-2458
41. Wester P, Bergstrom U, Eriksson A, Gezelius C, Hardy J, Winblad B (1990) Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J Neurochem 54:1148-1156